慢性髓性白血病中的干扰素:它对无治疗缓解有帮助吗?
Massimo Breccia1, Giuseppe Saglio2
1Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
British journal of haematology
|August 4, 2023
概括
干扰素α (IFNα) 在具有深度分子响应 (DMR) 的慢性髓性白血病患者中的作用尚不清楚. 将IFNα与尼罗丁尼结合使用可能会改善DMR的发生率,从而有可能使治疗停止.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 慢性髓性白血病 (CML) 治疗的目标是深度分子响应 (DMR).
- 干扰素-α (IFNα) 在获得DMR的CML患者中的作用尚不清楚.
- 第二代氨酸激酶抑制剂 (TKI),如尼洛丁尼,是标准的CML治疗.
研究的目的:
- 在CML患者中研究IFNα与尼罗丁尼结合的生物效应.
- 探索潜在的策略,以提高DMR的速度.
- 评估在患有DMR的CML患者中中止治疗的可行性.
主要方法:
- 评估尼洛尼和IFNα组合的前性研究.
- 监测CML患者的分子反应.
- 免疫调节效应的分析.
主要成果:
- 伊朗人和其他人的研究. 提供了对组合疗法的生物效应的见解.
- 组合疗法显示出增强深层分子响应 (DMR) 的潜力.
- 根据这些发现,需要进行进一步的临床研究.
结论:
- 将IFNα与尼罗丁尼结合使用可能会提高CML患者的DMR率.
- 这种方法可能会导致治疗中断成功的增加.
- 建议进行进一步的临床研究以验证这些发现.
更多相关视频
10:10Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
13.7K
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
12.1K
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
